- lithospermic acid
-
- $33.00 / 1mg
-
2024-11-19
- CAS:28831-65-4
- Min. Order:
- Purity: 99.6%
- Supply Ability: 10g
- Lithospermic acid
-
- $0.00 / 20mg
-
2023-02-24
- CAS:28831-65-4
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- lithospermic acid
-
- $15.00 / 1KG
-
2021-07-13
- CAS:28831-65-4
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | lithospermic acid Basic information |
| Product Name: | lithospermic acid | | Synonyms: | lithospermic acid;4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid;Aids071478;Aids-071478;Clinopodic acid H;(2S,3S)-4-[(E)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylic acid;3-Benzofurancarboxylic acid, 4-[(1E)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxo-1-propen-1-yl]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-, (2S,3S)-;(2S,3S)-4-((E)-3-((R)-1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carboxylic acid | | CAS: | 28831-65-4 | | MF: | C27H22O12 | | MW: | 538.46 | | EINECS: | | | Product Categories: | chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract | | Mol File: | 28831-65-4.mol |  |
| | lithospermic acid Chemical Properties |
| Melting point | 183-188 °C | | Boiling point | 862.6±65.0 °C(Predicted) | | density | 1.642±0.06 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | Soluble in methan | | form | powder | | pka | 2.77±0.10(Predicted) | | color | White |
| | lithospermic acid Usage And Synthesis |
| Uses | Shikoric acid has the functions of improving kidney function, preventing and treating cardiovascular diseases, and anti-oxidation. | | Biological Activity | Lithospermic acid, a plant-derived polycyclic phenolic carboxylic acid isolated from Salvia miltiorrhiza, has antioxidant and hepatoprotective activities against CCl4-induced acute and in vitro liver injury. | | in vivo | Lithospermic acid (50 mg/kg, po for 6 days) exhibits cardioprotective efficacy against MI/R injury in mouse models[2].
Lithospermic acid (10-30 mg/kg, po, single dose) exhibits uric acid lowering and anti-inflammatory effects in rats hyperuricemia and gouty arthritis models[3].
| Animal Model: | C57BL/6 mouse MI/R injury models[2] | | Dosage: | 50 mg/kg | | Administration: | po for 6 days | | Result: | Improved MI/R-induced cardiac dysfunction. |
| Animal Model: | Hyperuricemia and gouty arthritis model[3] | | Dosage: | 10-30 mg/kg | | Administration: | po, single dose | | Result: | Reduced the serum uric acid and monosodium urate crystal-induced paw edema. |
| | target | ROS | ERK | MMP(e.g.TIMP) | DNA/RNA Synthesis | Caspase | TNF-α | HIV | SOD | GPx | Xanthine oxidas | MPO | MDA |
| | lithospermic acid Preparation Products And Raw materials |
|